岸迈生物拟港股上市 中国证监会要求补充说明本次发行上市前后是否持续符合外商投资准入政策要求等

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional documentation from 12 companies, including Chaimai Biotech, regarding compliance with foreign investment policies prior to their public listing [1][2]. Group 1: Regulatory Requirements - CSRC has asked Chaimai Biotech to provide a conclusive legal opinion on the legality of past equity changes of its main domestic operating entity, including compliance with foreign exchange registration and foreign investment regulations [2]. - The company is required to clarify the establishment and equity changes of its largest shareholder, Sanaron Inc., and the relationship between the actual controller and trust beneficiaries [2]. - Chaimai Biotech must also disclose the natural person shareholders of Everlasting Wisdom Holdings Limited, which holds 5.37% of its shares, and explain the reasons and fairness of their investment [2]. Group 2: Business Overview - Chaimai Biotech is a clinical-stage biotechnology company focused on developing T-cell engagers for treating various cancers and autoimmune diseases [3][4]. - The company's oncology pipeline includes three clinical-stage candidates: EMB-01 for colorectal cancer, EMB-06 for multiple myeloma, and EMB-07 for lymphoma and solid tumors [4]. - Additionally, Chaimai Biotech has three preclinical candidates targeting different antigens, as well as an immunology pipeline with one clinical-stage candidate and two preclinical candidates [4].